ALCANZA Phase 3 trial

March 29, 2019

UK’s NICE Recommends Adcetris as Second-line Treatment for Certain CTCL Patients

News

After first rejecting it due to cost-effectiveness concerns, the National Institute for Health and Care Excellence (NICE) has now recommended the use of Adcetris (brentuximab vedotin) as a second-line therapy for patients with CD30-positive cutaneous T-cell ... Read more

January 10, 2019

Adcetris Not Cost-effective as Second-line Therapy for Some CTCL, U.K. Board Rules

News

The United Kingdom’s National Institute for Health and Care Excellence (NICE) concluded that Adcetris (brentuximab vedotin) is not a cost-effective option when given as a second-line therapy to people with ... Read more

January 24, 2018January 26, 2018

EU Approves Adcetris for Certain Types of Cutaneous T-cell Lymphoma

News

The European Commission has approved Adcetris (brentuximab vedotin) as a treatment for adults with cutaneous T-cell lymphoma (CTCL) whose cancer produces the CD30 molecule. It had previously given the therapy ... Read more

November 15, 2017November 15, 2017

EMA Urges European Commission to Approve Takeda’s Adcetris as Therapy for CTCL

News

European regulators have endorsed the use of Takeda‘s Adcetris (brentuximab vedotin) to treat a specific type of cutaneous T-cell lymphoma (CTCL). The Brussels-based Committee for Medicinal Products for Human Use ... Read more

August 18, 2017

Adcetris Might Be Approved for CTCL by December, as FDA Reviews Marketing Application

News

The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) required to bring Seattle Genetics’ Adcetris (brentuximab vedotin) to the market for the treatment ... Read more